通过泛HLA抗体W6/32识别人类白细胞抗原I类分子的结构基础
Phillip Pymm1, Philippa M Saunders2, Sushma Anand1
1Infection and Immunity Program, Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.
Journal of immunology (Baltimore, Md. : 1950)
|August 2, 2024
概括
W6/32抗体识别了人类白细胞抗原I类 (HLA-I) 分子上的保存表位,这对免疫反应至关重要. 这项研究绘制了W6/32表位,揭示了它与免疫受体相互作用的部位.
科学领域:
- 免疫学 免疫学 免疫学
- 结构生物学 结构生物学
- 分子生物学分子生物学
背景情况:
- 人类白细胞抗原I类 (HLA-I) 分子为免疫系统提供.
- HLA-I的极端多态性使研究复杂化.
- W6/32单克隆抗体 (mAb) 识别了跨HLA-I全型的保存表位,有助于研究.
研究的目的:
- 为了确定W6/32 mAb.Ab.所识别的表观图,我们要确定地图.
- 了解W6/32对HLA-I保持结合的结构基础.
主要方法:
- 与酸-HLA-B*27:05.05复合的W6/32 Fab片段的X射线晶体学
- 在HLA-I.上对W6/32表位的结构分析.
主要成果:
- 晶体结构显示,W6/32在HLA-I.的结槽下结合.
- 该表位是不连续的,涉及HLA-I和β2-微型血球蛋白的α1,α2和α3域.
- W6/32表位是低多态的区域,这解释了其泛HLA-I反应性.
- 该表位不会重叠T细胞受体或杀伤细胞Ig类受体结合部位,但会重叠白细胞Ig类受体和CD8核受体部位.
结论:
- W6/32表位图提供了对HLA-I识别的结构性见解.
- 结合W6/32会影响与白细胞Ig类受体和CD8核受体的相互作用.
- 了解W6/32表位素有助于解释其在免疫学研究和治疗策略中的使用.
相关概念视频
Antigens Involved in Adaptive Immunity
479
An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and...
Complete Antigens
Complete antigens possess both immunogenicity and...
479
Antigen Processing Pathways
973
MHC molecules are key players in the immune response, enabling T cells to recognize and respond to specific antigens. They are present on the surface of all nucleated cells in the body and are instrumental in presenting antigens to T cells and activating them. T cells recognize the MHC-antigen complex and initiate an immune response. MHC class I and MHC class II are two main types of MHC molecules, each associated with a distinct antigen processing pathway.
MHC Class I: Presenting Endogenous...
MHC Class I: Presenting Endogenous...
973


